Drug Type Trispecific T-cell engager (TriTE) |
Synonyms W333021 |
Target |
Action inhibitors, stimulants |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | United States | 07 Jan 2025 | |
Autoimmune Diseases | Preclinical | China | 07 Jan 2025 | |
Inflammation | Preclinical | United States | 07 Jan 2025 | |
Inflammation | Preclinical | China | 07 Jan 2025 |